- Home
- BANR vs PHVS Comparison
BANR vs PHVS Comparison
Compare BANR & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANR | PHVS |
|---|---|---|
| Founded | 1890 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BANR | PHVS |
|---|---|---|
| Price | $61.87 | $29.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $71.20 | $40.70 |
| AVG Volume (30 Days) | ★ 280.1K | 155.6K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.30% | N/A |
| EPS Growth | ★ 15.57 | N/A |
| EPS | ★ 5.64 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $5.69 | N/A |
| P/E Ratio | $10.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.01 | $11.51 |
| 52 Week High | $69.83 | $29.80 |
Technical Indicators
Market Signals| Indicator | BANR | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 59.64 | 63.12 |
| Support Level | $61.73 | $24.55 |
| Resistance Level | $65.31 | $29.80 |
| Average True Range (ATR) | 1.25 | 1.31 |
| MACD | 0.42 | 0.29 |
| Stochastic Oscillator | 99.33 | 88.11 |
Price Performance
Historical ComparisonAbout BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.